Elevai Labs Inc. reported its financial results for the third fiscal quarter ended September 30, 2024, on November 14, 2024. The company's revenue for the quarter was US$527.5 thousand, representing a 4.9% decrease from the third quarter of 2023.
The company reported a loss per share of US$0.068 for the third quarter of 2024, which is an improvement compared to a loss of US$0.078 per share in the same period last year. CEO Graydon Bensler stated that the quarter was a period of meaningful and strategic progress, including strengthening the financial position with an $8 million public offering.
Elevai Labs is actively exploring strategic, value-driven acquisitions and potential spin-out opportunities to drive value for customers and shareholders. The company continues to operate through its subsidiaries: Elevai Skincare, Elevai Biosciences, and Elevai Research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.